Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
troculeucel
- Development stage
- Phase 2
- Lead developer
- NKGen Biotech, Inc.
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Troculeucel is a novel, patient-specific, *ex vivo* expanded autologous natural killer (NK) cell immunotherapeutic drug candidate developed by NKGen Biotech. It is intended for the treatment of neurodegenerative disorders, including moderate Alzheimer's disease, and a broad range of cancers. Troculeucel uses the patient's own NK cells, which are collected, expanded outside the body without genetic modification to enhance their immunoregulatory and cytotoxic potential, and then reinfused into the same patient. The therapy has demonstrated an ability to cross the blood-brain barrier and improve cerebrospinal fluid biomarkers associated with neurodegeneration (such as amyloid-beta, phosphorylated tau protein, glial fibrillary acidic protein [GFAP], and neurofilament light chain [NfL]). Clinical trials have shown that troculeucel is well tolerated and may stabilize or improve cognitive function in patients with moderate Alzheimer's disease. The drug has received FDA Fast Track designation for this indication.
- Brand names
- SNK01SNK-01SNK 01
- Other names
- autologous natural killer cells SNK01Super Natural Killer Cells 01
02
Targets
NKG2DL (NKG2D ligands)
Beyond the preview
Go deeper on troculeucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on troculeucel.